Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab or Golimumab in Chronic Sarcoidosis
NCT00955279Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2009
- Primary completion
- May 2012
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial in sarcoidosis comparing Placebo, Golimumab and Ustekinumab (3 arms). Primary endpoint: Percent-predicted Forced Vital Capacity at 16 weeks. Started Nov 2009; status: completed.
02
Drugs
ustekinumabgolimumab
03
Conditions
sarcoidosis
Beyond the preview
Go deeper on NCT00955279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00955279.